Meeting the unique challenges of drug discovery for neurodegenerative diseases
Citation:
BMC Neurology
2009
9(Suppl 1):I1
Volume 9 Supplement 1
Proceedings of the 2009 Drug Discovery for Neurodegeneration Conference
Proceedings
Edited by Diana W Shineman and Howard M Fillit
The conference and the publication of these proceedings were supported by conference grant U13-AG031125 from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke and the National Institutes of Health's Office of Rare Diseases. Other sponsors: CoMentis, Eli Lilly and Company, sanofi-aventis, Biogen Idec and The Michael J. Fox Foundation for Parkinson's Research
Drug Discovery for Neurodegeneration Conference. Go to conference site.
Washington, DC, USA2-3 February 2009
-
-
ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
The advent of early absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening has increased the attrition rate of weak drug candidates early in the drug-discovery process, and decreased t...
Citation: BMC Neurology 2009 9(Suppl 1):S1 -
The basics of preclinical drug development for neurodegenerative disease indications
Preclinical development encompasses the activities that link drug discovery in the laboratory to initiation of human clinical trials. Preclinical studies can be designed to identify a lead candidate from sever...
Citation: BMC Neurology 2009 9(Suppl 1):S2 -
Characteristics of compounds that cross the blood-brain barrier
Substances cross the blood-brain barrier (BBB) by a variety of mechanisms. These include transmembrane diffusion, saturable transporters, adsorptive endocytosis, and the extracellular pathways. Here, we focus ...
Citation: BMC Neurology 2009 9(Suppl 1):S3
Annual Journal Metrics
-
Citation Impact
2.903 - 2-year Impact Factor (2021)
3.189 - 5-year Impact Factor (2021)
1.094 - SNIP (Source Normalized Impact per Paper)
0.772 - SJR (SCImago Journal Rank)Speed
50 days to first decision for all manuscripts (Median)
58 days to first decision for reviewed manuscripts only (Median)Usage
2,598,639 Downloads (2021)
2,061 Altmetric mentions (2021)